Clinical trial
A Randomized, Multicenter, Phase 3 Trial of Anlotinib Plus Immunochemoradiotherapy vs Immunochemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma
NCT07385079 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Multicenter, Phase 3 Trial of Anlotinib Plus Immunochemoradiotherapy vs Immunochemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma
- Lead sponsor
- Sun Yat-sen University
- Phase
- Phase 3
- Overall status
- Not yet recruiting
- Start date
- March 1, 2026
- Completion date
- January 1, 2030
- Enrollment
- 412 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
nasopharyngeal cancer, nasopharyngeal cancinoma (npc)